Sementis
Sydney, Australia· Est.
Sementis leverages a novel vaccinia‑based platform to create curative allergy vaccines that retrain immune memory.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Sementis leverages a novel vaccinia‑based platform to create curative allergy vaccines that retrain immune memory.
ImmunologyAllergy
Technology Platform
The Sementis Copenhagen Vector (SCV) is a fourth‑generation, replication‑deficient vaccinia viral vector with a large genetic capacity and plug‑and‑play capability, enabling rapid development of multi‑allergen therapeutic vaccines.
Opportunities
A curative, short‑course allergy vaccine could capture a large unmet market and the SCV platform can be extended to multiple allergens and other immunological indications.
Risk Factors
Regulatory approval of a novel viral vector, safety concerns, and competition from established allergen immunotherapy approaches.
Competitive Landscape
Few companies focus on curative allergy vaccines; Sementis differentiates through its SCV platform that delivers durable immune memory and blocking antibodies, unlike conventional desensitization or passive antibody therapies.